Respiratory Viral Articles & Analysis
24 news found
Funding from the BARDA Division of Research, Innovation, and Ventures (DRIVe) enabled the company to reformulate LMN-301, previously developed for oral delivery, and to evaluate its potential as an anti-viral therapeutic delivered to the respiratory tract, the primary site of SARS-CoV-2 infection. ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
Adverse events that were more commonly observed with Dupixent compared to placebo included injection site reactions (18% Dupixent, 13% placebo), viral upper respiratory tract infections (12% Dupixent, 10% placebo) and eosinophilia (7% Dupixent, 1% placebo). ...
Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies Expanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of BK viremia in kidney transplant recipients; initial data submitted for presentation in 1H 2022 Advancing two additional virus-specific T cell ...
ByKalaris
Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio™ was shown to reduce the infectious viral load by more than 99% when used for prevention. Further, Bentrio™ was effective in slowing the ...
Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio™ was shown to reduce the infectious viral load by more than 99% when used for prevention. Further, Bentrio™ was effective in slowing the ...
The primary efficacy endpoint is the reduction in viral load at Week 4. About Respiratory Viral Infections and the ALVR106 Phase 1/2 Study Upper respiratory tract infections due to hMPV, influenza, PIV and RSV are detected in up to 40% of allo-HCT patients. In approximately half of these patients, these viral ...
ByKalaris
In a recent article, Prof Daniel Salerno, Prof Victor Kim and colleagues used Functional Respiratory Imaging to better understand the crucial link between DLCO and Pulmonary Vascular Abnormalities in COVID19. COVID-19 is a respiratory viral illness causing pneumonia and systemic disease. Abnormalities in pulmonary function tests infection have ...
ByFluidda
Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Emergency Department at Box Hill Hospital in Melbourne, Australia, has initiated a 300-subject investigator-led trial using Lumos’ FebriDx® POC test to rapidly identify patients presenting with a suspected viral infection consistent with COVID-19. This ...
Data will be presented at American Society for Virology (ASV) 2021 and are available on bioRxiv REDWOOD CITY, Calif., July 19, 2021 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the release of preclinical data in nonhuman primates (NHPs) of the ...
Paul Rota, Chief of the CDC’s Viral Vaccine Preventable Diseases Branch. Enrollment for the clinical trial is expected to continue through the second half of 2021, with results expected to be available in the first half of 2022. ...
· No vaccine is currently approved to protect against respiratory syncytial virus (RSV) · RSV is the leading cause of infant hospitalization in the United States and is considered the “missing” pediatric vaccine · Previous clinical data in seropositive adult and pediatric participants showed MV-012-968 was well-tolerated, appropriately ...
This is the platform that is used to screen for disease indications such as bacterial and viral respiratory tract infections, Group B Streptococcus infection, lung cancer and other chronic inflammatory respiratory conditions. ...
Initial preclinical data shows MV-014-212 induced a SARS-CoV-2-specific mucosal IgA response, generated serum neutralizing antibodies, and provided efficacy against challenge REDWOOD CITY, Calif., March 16, 2021 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, ...
The GC-IMS platform already has proven capability in differentiating between bacterial and viral respiratory infections as well as detecting a range of other infectious and inflammatory diseases and ...
- The randomized, double-blind, placebo-controlled challenge study is designed to evaluate safety and prophylactic efficacy of MV-012-968 against symptomatic respiratory syncytial virus (RSV) - Previous clinical data shows MV-012-968 is well-tolerated, heavily attenuated, and induces an RSV-specific mucosal IgA response in healthy seropositive adults and pediatric participants ...
The Imspex Group’s BreathSpec technology is well-placed to play a leading role in combatting antimicrobial resistance by helping healthcare practitioners to differentiate between bacterial and viral causes of respiratory infection. This would better allow the right antibiotic to be prescribed to the right patient at the right time and in the right dose , ...
The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or Influenza B and/or Respiratory ...
Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific mucosal IgA ...
Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, announced today that it has entered into a research collaboration with Janssen Pharmaceuticals, Inc., (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to advance Alveo’s be.well™ platform of analyzers, nasal ...